Stock Ratings / Health Care / LEGN / options

EWTX (41) INDV (51) LQDA (36) ARQT (54) ⌘ Pro Terminal →

Legend Biotech Corporation (LEGN) Options Positioning, Max Pain & Unusual Sweeps

$21.63 -3.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.47

Legend Biotech Corporation (LEGN) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $4.21B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LEGN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LEGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Legend Biotech Corporation (NASDAQ: LEGN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $21.63 (-3.00% 1D, market cap $4.21B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, LEGN ranks #163 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LEGN compare to EWTX and INDV in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEGN carries a Roarable C- (60/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, EWTX (Edgewise Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.9%, cap $4.22B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LEGN?

▼

For Legend Biotech Corporation (LEGN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #163 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.47 (-0.73%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 2.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LEGN)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (60/100 Composite)

🔍 WHY LEGN SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (27% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (20% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (59.2) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$19.04-2.2% Next Q

Q2 (-2Q)

Grade C$18.63+20.9% Next Q

Q3 (-1Q)

Grade C$22.53-4% Next Q

Current

Grade C-$21.63+0.4% Hist 90D α

Trajectory: C- (52) → C- (60)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LEGN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 60/100 (C-) score, LEGN faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($19.60) or 200D SMA ($22.13) invalidates the momentum regime and cuts Target Base ($21.82) toward Bear Floor ($17.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LEGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LEGN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 60%NO 40%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±11%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (LEGN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for LEGN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating LEGN & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on LEGN
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LEGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.38%⚡ TESTING RESISTANCE

2026-11-03O $22.30H $22.30L $21.63C $21.63VOL 2.19M

RES: $22.95SUP: $15.25SMA50: $19.60SMA200: $22.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LEGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LEGN Butterfly Map → + Track LEGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LEGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LEGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LEGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LEGN)

Health Care Rank #163 of 1016 ⚔️ EWTX vs LEGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LEGN vs. EWTX, INDV, LQDA, ARQT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Legend Biotech Corporation (LEGN) ranks #163 by composite RQD confidence (60/100, grade C-) and #175 by equity capitalization ($4.21B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. LEGN currently leads its immediate peer cohort in composite quantitative strength at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LEGN ACTIVE Legend Biotech Corporation	C-	60/100	32.8x	—	9.9%	-3.00%	$4.21B	Benchmark Subject
EWTX Edgewise Therapeutics Inc.	D-	41/100	—	—	-31.9%	-0.03%	$4.22B	/ewtx-vs-legn →
INDV Indivior Pharmaceuticals Inc.	D	51/100	19.8x	80.2%	62.2%	+0.34%	$4.17B	/indv-vs-legn →
LQDA Liquidia Corporation	D-	36/100	—	—	-12.6%	+0.16%	$4.03B	/lqda-vs-legn →
ARQT Arcutis Biotherapeutics Inc.	D+	54/100	—	90.2%	-3.0%	+0.31%	$4.03B	/arqt-vs-legn →

2. LEGN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Legend Biotech Corporation (LEGN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.21B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. LEGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LEGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LEGN compare to EWTX and INDV in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LEGN?

Where is LEGN trading relative to its 50-day, 200-day, and 52-week technical levels?

LEGN last traded at $21.63 (-3.00% on volume of 2,189,710 shares), positioning the stock +10.36% above its 50-day simple moving average ($19.60) and -2.26% below its 200-day simple moving average ($22.13). Across its 52-week range of $16.24 to $37.50, LEGN sits at the 25.4% percentile with a 14-day RSI of 59.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.0% ($19.25 to $24.01).

LEGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LEGN's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for LEGN.

Direct Sub-Reports: LEGN RQD Cockpit LEGN 12M Forecast LEGN Earnings & Move LEGN Dividends & DRIP LEGN Insiders & 13F LEGN Whale Options LEGN Profit Sankey LEGN News & Why

ROARABLE RATING BRIEF • RQD 60/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LEGN — Legend Biotech Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:11:28Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LEGN scores 64 out of 100, a letter grade of C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

Fundamental Cash Engine: 11 / 20. Per the RQD rating, this reflects ROIC of 9.9% and an FCF yield of 2.21%. For an investor, returns on capital are positive but modest, and the cash yield at the current price is thin, so the stock is not being priced as a cash-generation story.
Whale 13F Flow: 12 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. The score is mid-range, indicating neither strong net accumulation nor distribution in the sourced data.
Insider Conviction: 12 / 20. Per the RQD rating, this covers SEC Form 4 and Congressional PTR cluster flow. The mid-range score suggests insider signals are not a decisive positive or negative.
Macro Regime Fit: 13 / 20. Per the RQD rating, beta is 1.04 and sector sensitivity is noted. The stock tracks broad market movement closely, so it offers little defensive diversification or outsized beta leverage.
Forensic Balance Sheet: 16 / 20. Per the RQD rating, Altman Z is 3.74, Piotroski F is 8/9, and Debt/Equity is 0.39. This is the strongest pillar, pointing to a financially sound balance sheet with low leverage.

Implications for a prospective investor: the upside case rests on earnings growth and balance-sheet strength rather than on cash yield or insider signals. The valuation tradeoff is material: per the market data, P/E (TTM) is 32.8 and forward P/E is 30.5, so the price already embeds substantial expectations. The "Hold" verdict reflects that balance-sheet quality is offset by a demanding multiple, modest returns on capital, and mid-range flow signals. This is an analytical framing, not personalized financial advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
22.3	$4.34B	32.8	30.5	21	0.68	0%	1.04	$16.24 - $37.5	9.9%

Recent Catalysts & News Wire Analysis

Per the recent news section, the feed contains six items, five flagged YELLOW (Market Wire) and one flagged RED (Risk Watch):

Breakout and moving-average signals (YELLOW): Headlines report the stock breaking out above its 200-day moving average and crossing above its 50-day moving average. These are technical market-action items, not fundamental events.
Profitability commentary (YELLOW): A Seeking Alpha headline characterizes Carvykti as generating large revenue while profits remain elusive. This is a third-party opinion and should be weighed as such.
Analyst and forecast coverage (YELLOW): A Simply Wall St item covers forecasts and analyst predictions; the content of those predictions is not provided in source data.
Regulatory catalyst (YELLOW): A Stock Titan headline reports FDA clearance of a study application for a therapy designed to make immune cells inside the body. This is the only sourced regulatory milestone.
Risk Watch (RED): A Stock Traders Daily item on risk zones is flagged RED. The feed does not specify the risk mechanism.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream links, sector correlations, or 2nd-order bottlenecks are recorded. Not available in source data for supplier, partner, or customer dependencies.

Open Questions

What are the revenue, operating income, and net income figures by period, given that no financials are provided?
Why is gross margin recorded as 0% when operating margin is 13.9%, and is this a data-reporting artifact?
What is the mechanism behind the RED Risk Watch flag, and does it relate to the Carvykti profitability commentary?
What are the consensus rating and price targets, and how do they compare with the 30.5 forward P/E?
What institutional, insider, and Congressional flows underlie the 12/20 flow pillars, given that holder data is absent?

LEGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Legend Biotech Corporation (LEGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LEGN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 19h ago

Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average

Yahoo Finance report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 22h ago

Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive

Seeking Alpha report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Legend Biotech (NasdaqGS:LEGN) Stock Forecast & Analyst Predictions

Simply Wall St report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors

Yahoo! Finance Canada report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

FDA clears a study application for a therapy designed to make immune cells inside the body

Stock Titan report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Traders Daily • 1d ago

Precision Trading with Legend Biotech Corporation (LEGN) Risk Zones

Stock Traders Daily report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH ad-hoc-news.de • 1d ago

JPMorgan cuts target for Legend Biotech stock to USD 33

ad-hoc-news.de report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Legend Biotech stock: FDA clears LB2501. What it means for Legend Biotech stock

ad-hoc-news.de report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LEGN Bull vs. Bear Conversation Board — What's Your Call at $21.63?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LEGN 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $24.08 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LEGN (C • RQD 64/100) a Buy at $22.30?

Welcome to the LEGN (Legend Biotech Corporation) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $17.39 (-22.0%)

Spot @ $22.30

Pump the brakes on LEGN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LEGN, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Legend Biotech Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $27.88 (+25.0%)

Spot @ $22.30

LEGN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LEGN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $22.30 (52-wk range $16.24 - $37.50), any beat on forward guidance forces shorts and underweight funds to chase.